ID CLB HC.PH.BIO.CLB
Develops drugs, biologics or cell and gene therapies with no approved product on the market (no revenue, or milestones only); such a developer is here, not in contract research.
Sector, group and industry above this class, as placed in the current release. The sector and the industry link to their companies.
Companies whose primary class this is. The sector and industry pages and the screener count them the same way.
| Company | Ticker | Country | Market cap | Filings |
|---|---|---|---|---|
| Lantern Pharma Inc. | LTRN | United States of America | $47.72M | 307 |
| Barinthus Biotherapeutics plc. | BRNS | United Kingdom | $22.10M | 284 |
| Alzinova AB | ALZ | Sweden | $21.75M | 845 |
| NanoGroup S.A. | NNG | Poland | $28.84M | 1,049 |
| AlzeCure Pharma | ALZCUR | Sweden | $21.28M | 656 |
| BullFrog AI Holdings, Inc. | BFRG | United States of America | $13.67M | 199 |
| Poltreg S.A. | PTG | Poland | $20.82M | 374 |
| Aelis Farma | AELIS | France | $20.51M | 184 |
| Isofol Medical | ISOFOL | Sweden | $20.25M | 244 |
| Yarrow Bioscience, Inc. | YARW | United States of America | $21.88M | 703 |
| NANOVIRICIDES, INC. | NNVC | United States of America | $30.57M | 549 |
| EXACT Therapeutics AS | EXTX | Norway | $9.80M | 285 |
| BerGenBio | BGBIO | Norway | $19.16M | 1,009 |
| Lipidor AB Delisted | LIPI | Sweden | $18.72M | 429 |
| Allarity Therapeutics, Inc. | ALLR | United States of America | $17.98M | 395 |
| Polyrizon Ltd. | PLRZ | United States of America | $24.32M | 189 |
| Quantum Biopharma Ltd. | QNTM | Canada | $18.23M | 356 |
| SoftOx Solutions AS | SOFTX | Norway | $29.16M | 622 |
| Tevogen Inc. | TVGN | United States of America | $24.35M | 303 |
| Pasithea Therapeutics Corp. | KTTA | United States of America | $19.55M | 331 |
| Cue Biopharma, Inc. | CUE | United States of America | $112.99M | 566 |
| Medicus Pharma Ltd. | MDCX | Canada | $19.83M | 328 |
| Cocrystal Pharma, Inc. | COCP | United States of America | $14.06M | 569 |
| Active Biotech | ACTI | Sweden | $15.85M | 887 |
| Marker Therapeutics, Inc. | MRKR | United States of America | $16.82M | 910 |
| Celyad Oncology SA | CYAD | Belgium | $12.17M | 1,081 |
| OSR Health, Inc. | OSRH | United States of America | $11.83M | 225 |
| Genenta Science S.p.A. | GNTA | Italy | $34.91M | 116 |
| NFL Biosciences | ALNFL | France | $12.64M | 209 |
| SYNAIRGEN PLC | SNG | United Kingdom | $15.45M | 385 |
| Phio Pharmaceuticals Corp. | PHIO | United States of America | $14.87M | 892 |
| Applied Therapeutics, Inc. Delisted | APLT | United States of America | $14.86M | 504 |
| Moleculin Biotech, Inc. | MBRX | United States of America | $12.81M | 843 |
| INTENSITY THERAPEUTICS, INC. | INTS | United States of America | $10.03M | 253 |
| GENFLOW BIOSCIENCES PLC | GENF | United Kingdom | $15.53M | 154 |
| Toleranzia AB Delisted | TOL | Sweden | $13.83M | 538 |
| IN8BIO, INC. | INAB | United States of America | $13.49M | 419 |
| BioAtla, Inc. | BCAB | United States of America | $13.34M | 520 |
| Curanex Pharmaceuticals Inc | CURX | United States of America | $8.59M | 61 |
| JUPITER NEUROSCIENCES, INC. | JUNS | United States of America | $13.07M | 196 |
| BenevolentAI Delisted | BAI | Luxembourg | $13.01M | 124 |
| GT Biopharma, Inc. | GTBP | United States of America | $12.92M | 878 |
| BioCardia, Inc. | BCDA | United States of America | $12.84M | 1,122 |
| Rocket One Inc. | RKTO | United States of America | $12.50M | 344 |
| Stem Cells Spin Spolka Akcyjna | SCS | Poland | $12.30M | 709 |
| Cadrenal Therapeutics, Inc. | CVKD | United States of America | $12.16M | 279 |
| Chemomab Therapeutics Ltd. | CMMB | United States of America | $11.38M | 1,423 |
| Vyome Holdings, Inc | HIND | United States of America | $11.94M | 604 |
| Traws Pharma, Inc. | TRAW | United States of America | $11.69M | 987 |
| CytoMed Therapeutics Ltd | GDTC | Singapore | $12.19M | 132 |
Other names for this activity, and where neighboring activities go instead.
preclinicaldrug developer
Research-led company whose approved medicines, which it discovered, are in one or two therapeutic areas; it moves to Branded Prescription Drugs only after two consecutive annual reports with approved products in three or more.
https://financialfilings.com/oics/CLB/
This page is keyed by the class ID CLB. IDs are assigned in v0.3 and freeze at v1.0; from then on an ID is never renamed or reused, and if the class moves in the tree, its ID and this URL stay the same.
Sign in or create a free account - no password needed.
By continuing, you agree to our Terms and Privacy Policy.